GHADA AL-ASADI: Open Payments
NPI 1598875239 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,506 in 65 payments from 13 companies in 2025. Trend: 2023 $2,290 · 2024 $1,182 · 2025 $1,506
Food & beverage: $1,507
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 15 | $438 |
| Otsuka America Pharmaceutical, Inc. | 10 | $222 |
| ABBVIE INC. | 12 | $172 |
| Teva Pharmaceuticals USA, Inc. | 6 | $121 |
| Alkermes, Inc. | 5 | $110 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $101 |
| Alpha Cognition USA, Inc. | 2 | $93 |
| E.R. Squibb & Sons, L.L.C. | 3 | $78 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $57 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
Products named: HETLIOZ, REXULTI, VRAYLAR, ARISTADA, CAPLYTA, UZEDY, Zunveyl, COBENFY.
Industry payments across CA — which companies pay providers there.
